<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412799</url>
  </required_header>
  <id_info>
    <org_study_id>CL-SBP-101-03</org_study_id>
    <nct_id>NCT03412799</nct_id>
  </id_info>
  <brief_title>Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer</brief_title>
  <official_title>Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Panbela Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Panbela Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase 1A/1B study to assess the safety, tolerability and&#xD;
      pharmacokinetics of SBP-101 when combined with nab-paclitaxel and gemcitabine in subjects&#xD;
      with previously untreated metastatic pancreatic ductal adenocarcinoma and to identify a&#xD;
      recommended phase 2 dose. The study will also assess preliminary efficacy of the 3-drug&#xD;
      treatment combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be conducted in two phases: dose escalation and expansion. Up to three dose&#xD;
      levels of SBP-101 will be assessed in up to 18 subjects during dose escalation. The expansion&#xD;
      phase of the study will consist of 10 additional subjects who will receive the recommended&#xD;
      dose of SBP-101 combined with nab-paclitaxel and gemcitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose of SBP-101</measure>
    <time_frame>Up to 12 months following the first dose of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 24 months following the first dose of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response will be evaluated on RECIST definitions</measure>
    <time_frame>Every 8 weeks during treatment assessed up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) for all three drugs</measure>
    <time_frame>Day 1 of Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) for all three drugs</measure>
    <time_frame>Day 1 of Cycle 1</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pancreatic Cancer Metastatic</condition>
  <condition>Pancreatic Cancer Stage IV</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SBP-101</intervention_name>
    <description>Administered as subcutaneous (SC) injection, escalating dose cohorts</description>
    <other_name>diethyl dihydroxyhomospermine</other_name>
    <other_name>[(HO)2-DEHSPM]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Administered as intravenous (IV) infusion</description>
    <other_name>abraxane</other_name>
    <other_name>protein-bound paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Injection</intervention_name>
    <description>Administered as intravenous (IV) infusion</description>
    <other_name>gemcitabine hydrochloride</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma.&#xD;
             Patients with pancreatic acinar cell carcinoma may also be included.&#xD;
&#xD;
          -  Is previously untreated for metastatic pancreatic ductal adenocarcinoma, was diagnosed&#xD;
             within the past 3 months, and is expected to receive standard treatment with&#xD;
             gemcitabine and nab-paclitaxel.&#xD;
&#xD;
          -  Measurable disease on CT or MRI scan by RECIST v 1.1 criteria.&#xD;
&#xD;
          -  ECOG Performance Status 0 or 1.&#xD;
&#xD;
          -  Adult, age ≥ 18 years, male or female.&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative serum pregnancy test within 14&#xD;
             days prior to start of study treatment and must use an adequate method of&#xD;
             contraception during the study. All sexually active males must also use an adequate&#xD;
             method of contraception during the study. Female subjects will be considered to be of&#xD;
             childbearing potential unless they are postmenopausal (at least 12 months of&#xD;
             consecutive amenorrhea, without other known or suspected cause) and over 55 years old&#xD;
             or have been sterilized surgically (i.e., bilateral tubal ligation, hysterectomy or&#xD;
             bilateral oophorectomy, all with surgery at least one month before dosing).&#xD;
&#xD;
          -  Adequate bone marrow, hepatic, renal and coagulation function as defined by the&#xD;
             following:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1.5 x 109/L&#xD;
&#xD;
               2. Hemoglobin ≥9.0 g/dL (90 g/L)&#xD;
&#xD;
               3. Platelets ≥100 x 109/L&#xD;
&#xD;
               4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x upper&#xD;
                  limit of normal (ULN) (if no hepatic metastases). If hepatic tumor involvement,&#xD;
                  AST and ALT ≤5 x ULN.&#xD;
&#xD;
               5. Bilirubin ≤1.5 x ULN&#xD;
&#xD;
               6. Prothrombin time (PT) / international normalized ratio (INR) ≤1.5 x ULN if not on&#xD;
                  anti-coagulants&#xD;
&#xD;
               7. Calculated creatinine clearance &gt;50 mL/min using the Cockcroft and Gault equation&#xD;
&#xD;
          -  QTc interval ≤ 470 msec at Baseline.&#xD;
&#xD;
          -  Life expectancy ≥ 3 months.&#xD;
&#xD;
          -  Willing and able to provide written informed consent: voluntary agreement to&#xD;
             participate in the study following disclosure of risks and procedures required,&#xD;
             including possibility of onset of exocrine pancreatic insufficiency with subsequent&#xD;
             requirement for life-long pancreatic enzyme replacement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition that,&#xD;
             in the opinion of the Investigator or Medical Monitor, makes it undesirable for the&#xD;
             subject to participate in the study or that would jeopardize compliance with the&#xD;
             protocol. Subjects with pre-existing well-controlled diabetes are not excluded.&#xD;
&#xD;
          -  Medical or psychiatric conditions that compromise the subject's ability to give&#xD;
             informed consent or to complete the protocol or a history of non-compliance&#xD;
&#xD;
          -  Presence of islet-cell or pancreatic neuroendocrine tumor or mixed&#xD;
             adenocarcinoma-neuroendocrine carcinoma&#xD;
&#xD;
          -  Have symptomatic central nervous system (CNS) malignancy or metastasis. Screening of&#xD;
             asymptomatic subjects without history of CNS metastases is not required.&#xD;
&#xD;
          -  Serum albumin &lt;30 g/L (3.0 g/dL)&#xD;
&#xD;
          -  Evidence of deep vein thrombosis or pulmonary embolism or other thromboembolic event&#xD;
             during screening&#xD;
&#xD;
          -  Presence of known active bacterial, fungal, or viral infection requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Known active infection with human immunodeficiency virus (HIV), hepatitis B or C&#xD;
&#xD;
          -  Presence of interstitial lung disease, pulmonary fibrosis, or pulmonary&#xD;
             hypersensitivity reaction&#xD;
&#xD;
          -  Myocardial infarction within the last 12 months, severe/unstable angina, symptomatic&#xD;
             congestive heart failure New York Heart Association (NYHA) class III or IV&#xD;
&#xD;
          -  Maldigestion/malabsorption syndrome pre-dating the diagnosis of pancreatic cancer.&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Major surgery within 4 weeks of the start of study treatment, without complete&#xD;
             recovery&#xD;
&#xD;
          -  Known hypersensitivity to any component of study treatments&#xD;
&#xD;
          -  Participation in any other clinical investigation within 4 weeks of receiving the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Subjects taking metformin. Diabetics on treatment with metformin, or any other&#xD;
             derivative thereof, must discontinue it while on study. (Other diabetic medications&#xD;
             are allowed.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne Gagnon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Panbela Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sheri Smith</last_name>
    <phone>952-908-9986</phone>
    <email>ssmith@couranteoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tammy Groene</last_name>
    <phone>952-479-1196</phone>
    <email>tgroene@sunbiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps MD Anderson Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darren Sigal, MD</last_name>
      <phone>858-554-8788</phone>
      <email>Sigal.Darren@scrippshealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris LeFeber</last_name>
      <phone>585-275-0407</phone>
      <email>chris_lefeber@URMC.Rochester.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Blacktown Cancer &amp; Haematology Centre</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Tangunan</last_name>
      <phone>+61298818421</phone>
      <email>raymond.tanguanan@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Flynn Private Hospital</name>
      <address>
        <city>Tugun</city>
        <state>Queensland</state>
        <zip>4224</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumit Lumba, MBBS, FRACP</last_name>
      <phone>+61 7 5506 7374</phone>
      <email>sumitlumba@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ashford Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 8 8292 2240</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niall Tebutt, MBBS, FRACP</last_name>
      <phone>+61 3 9496 5000</phone>
      <email>niall.tebutt@onjcri.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Johnston</last_name>
      <phone>+61 9496 3038</phone>
      <email>catherine.johnston@austin.org.au</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

